Raising the alarm: fosfomycin resistance associated with non-susceptible inner colonies imparts no fitness cost to the primary bacterial uropathogen.
Tomas A Bermudez, John R Brannon, Neha Dudipala, Seth Reasoner, Grace Morales, Michelle Wiebe, Mia Cecala, Michael DaCosta, Connor Beebout, Omar Amir and 1 more
Article in Antimicrobial agents and chemotherapy, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.
0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
1.3field-weighted citation impact, top 18% of its field
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literature
Who cites it
7 citing papers in PubMed, 6 citations in OpenAlex.
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what money
Authors and funding
11 authors at 2 institutions in 1 country.
Tomas A BermudezDepartment of Pathology, Microbiology & Immunology, Vanderbilt University Medical Center , Nashville, Tennessee, USA.ORCID 0000-0002-1915-1293
John R BrannonDepartment of Pathology, Microbiology & Immunology, Vanderbilt University Medical Center , Nashville, Tennessee, USA.
Neha DudipalaVanderbilt University , Nashville, Tennessee, USA.
Seth ReasonerDepartment of Pathology, Microbiology & Immunology, Vanderbilt University Medical Center , Nashville, Tennessee, USA.ORCID 0000-0002-7791-1641
Grace MoralesDepartment of Pathology, Microbiology & Immunology, Vanderbilt University Medical Center , Nashville, Tennessee, USA.
Michelle WiebeDepartment of Pathology, Microbiology & Immunology, Vanderbilt University Medical Center , Nashville, Tennessee, USA.
Mia CecalaVanderbilt University , Nashville, Tennessee, USA.
Michael DaCostaVanderbilt University , Nashville, Tennessee, USA.
Connor BeeboutDepartment of Pathology, Microbiology & Immunology, Vanderbilt University Medical Center , Nashville, Tennessee, USA.
Omar AmirVanderbilt University , Nashville, Tennessee, USA.
Maria HadjifrangiskouDepartment of Pathology, Microbiology & Immunology, Vanderbilt University Medical Center , Nashville, Tennessee, USA.ORCID 0000-0003-4249-8997
Vanderbilt University Medical Center · USVanderbilt University · US
Funding
MEDICAL SCIENTIST TRAINING PROGRAMT32GM007347 · NIGMS · VANDERBILT UNIVERSITY · PI WILLIAMS, CHRISTOPHER S. · 1985 to 2023
$26.3M
CLINICAL PHARMACOLOGY TRAINING PROGRAMT32GM007569 · NIGMS · VANDERBILT UNIVERSITY MEDICAL CENTER · PI Bjorn C Knollmann · 1985 to 2026
$12.4M
Medical Scientist Training ProgramT32GM152284 · NIGMS · VANDERBILT UNIVERSITY · PI Christopher S. Williams · 2024 to 2026
$4.8M
How E. coli Acid Response Mechanisms Breach Colonization Resistance in the VaginaR01AI168468 · NIAID · VANDERBILT UNIVERSITY MEDICAL CENTER · PI Maria Hadjifrangiskou · 2022 to 2026
$2.9M
Cellular, Biochemical and Molecular Sciences Training ProgramT32GM137793 · NIGMS · VANDERBILT UNIVERSITY · PI Katherine Louise Friedman, TODD R GRAHAM · 2021 to 2026
$2.6M
Two-component system interactions as uropathogenic Escherichia coli drug targetsR01AI107052 · NIAID · VANDERBILT UNIVERSITY MEDICAL CENTER · PI HADJIFRANGISKOU, MARIA · 2015 to 2019
$1.9M
The Vanderbilt Urologic Infection Repository, a Resource for Personalized Clinical DiscoveryP20DK123967 · NIDDK · VANDERBILT UNIVERSITY MEDICAL CENTER · PI CLAYTON, DOUGLASS BROOKS, HADJIFRANGISKOU, MARIA · 2019 to 2020
$680k
Copper Sensing in Uropathogenic Escherichia coliF30AI169748 · NIAID · VANDERBILT UNIVERSITY · PI Seth A Reasoner · 2023 to 2026
$156k
The role of cytochrome bd in uropathogenic Escherichia coli pathogenesisF30AI150077 · NIAID · VANDERBILT UNIVERSITY · PI BEEBOUT, CONNOR JAMES · 2020 to 2022
$125k
The roles of fosfomycin resistant subpopulations of Escherichia coli in urinary tract infection.F31AI174488 · NIAID · VANDERBILT UNIVERSITY · PI BERMUDEZ, TOMAS ALEXANDER · 2023 to 2024
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.
Raising the alarm: fosfomycin resistance associated with non-susceptible inner colonies imparts no fitness cost to the primary bacterial uropathogen. · full record | OpenQuestion